

## Crohn's Disease Disturbs the Immune Properties of Human Adipose-Derived Stem Cells Related to Inflammasome Activation

Carolina Serena,<sup>1,2,\*</sup> Noelia Keiran,<sup>1,2,9</sup> Ana Madeira,<sup>1,2,9</sup> Elsa Maymó-Masip,<sup>1,2</sup> Miriam Ejarque,<sup>1,2</sup> Margarida Terrón-Puig,<sup>1</sup> Eloy Espin,<sup>3</sup> Marc Martí,<sup>3</sup> Natalia Borrueal,<sup>4</sup> Francisco Guarner,<sup>4</sup> Margarida Menacho,<sup>5</sup> Antonio Zorzano,<sup>2,6,7</sup> Monica Millan,<sup>8</sup> Sonia Fernández-Veledo,<sup>1,2</sup> and Joan Vendrell<sup>1,2,\*</sup>

<sup>1</sup>Unitat de Recerca, Hospital Universitari de Tarragona Joan XXIII, Institut d'Investigació Sanitària Pere Virgili, Universitat Rovira i Virgili, 43007 Tarragona, Spain

<sup>2</sup>CIBER de Diabetes y Enfermedades Metabólicas Asociadas (CIBERDEM), Instituto de Salud Carlos III, 28014 Madrid, Spain

<sup>3</sup>Colorectal Surgery Unit, General Surgery Service, Hospital Vall d'Hebron, Universitat Autònoma de Barcelona, 08035 Barcelona, Spain

<sup>4</sup>Digestive System Research Unit, University Hospital Vall d'Hebron, Centro de Investigación Biomédica en Red de Enfermedades Hepáticas y Digestivas (CIBEREHD), Universitat Autònoma de Barcelona, 08035 Barcelona, Spain

<sup>5</sup>Digestive Unit, Hospital Universitari Joan XXIII, 43007 Tarragona, Spain

<sup>6</sup>Institute for Research in Biomedicine (IRB Barcelona), 08028 Barcelona, Spain

<sup>7</sup>Departament de Bioquímica i Biologia Molecular, Facultat de Biologia, Universitat de Barcelona, 08193 Barcelona, Spain

<sup>8</sup>Colorectal Surgery Unit, Hospital Universitari Joan XXIII, 43007 Tarragona, Spain

<sup>9</sup>These authors contributed equally

\*Correspondence: [carolserena@gmail.com](mailto:carolserena@gmail.com) (C.S.), [jvo@comt.es](mailto:jvo@comt.es) (J.V.)

<http://dx.doi.org/10.1016/j.stemcr.2017.07.014>

### SUMMARY

Crohn's disease (CD) is characterized by the expansion of mesenteric fat, also known as “creeping fat.” We explored the plasticity and immune properties of adipose-derived stem cells (ASCs) in the context of CD as potential key players in the development of creeping fat. Mesenteric CD-derived ASCs presented a more proliferative, inflammatory, invasive, and phagocytic phenotype than equivalent cells from healthy donors, irrespective of the clinical stage. Remarkably, ASCs from the subcutaneous depot of patients with CD also showed an activated immune response that was associated with a reduction in their immunosuppressive properties. The invasive phenotype of mesenteric CD ASCs was governed by an inflammasome-mediated inflammatory state since blocking inflammasome signaling, mainly the secretion of interleukin-1 $\beta$ , reversed this characteristic. Thus, CD alters the biological functions of ASCs as adipocyte precursors, but also their immune properties. Selection of ASCs with the best immunomodulatory properties is advocated for the success of cell-based therapies.

### INTRODUCTION

Crohn's disease (CD) is becoming increasingly common and represents a significant burden to healthcare systems (Kappelman et al., 2008). CD is characterized by persistent inflammation and ulceration of the small or large bowel with an undulating course of activity, and frequently recurs after periods of remission.

Hyperplasia of the mesenteric fat adjacent to the inflamed regions of the intestine, so-called creeping fat (CF), is a hallmark of CD and seems to be directly related to disease activity (Buning et al., 2015; Connelly et al., 2014; Fink et al., 2012; Li et al., 2015). Indeed, it has been recently described that reoperation rates among CD patients decreases dramatically, from 27% to 2.7%, when mesenteric adipose tissue (AT) is included during intestinal resection (Coffey and O'Leary, 2016). While its function and pathological significance for CD remains largely unknown, CF is clearly related to inflammatory response (Desreumaux et al., 1999; Peyrin-Biroulet et al., 2007; Zulian et al., 2012) and shows abundant macrophage and T cell infiltrates (Zulian et al., 2012). CF is considered an invasive

form of mesenteric AT and, unlike obesity, its expansion surrounding inflamed intestinal tract tissue is dependent largely on adipocyte hyperplasia, with adipocytes 75% smaller than those from healthy subjects (Kredel and Siegmund, 2014; Zulian et al., 2012). AT hyperplasia results from the increase in adipocyte number via recruitment and differentiation of AT precursors termed AT-derived mesenchymal stem cells (ASCs) (Goncalves et al., 2015; Zulian et al., 2013). It is therefore possible that the origin of CF lies in the functional properties of ASCs. ASCs not only participate in turnover of mature adipocytes in humans (ca. 10% per year) but possess immunoregulatory properties that may be induced by the underlying pathological state (Pachon-Pena et al., 2016; Serena et al., 2016).

There is increasing data pointing to a connection between bacterial translocation and the development of CF (Batra et al., 2012; Peyrin-Biroulet et al., 2012). Because bacteria can trigger preadipocyte proliferation *in vitro* (Zulian et al., 2013), bacterial translocation might underlie AT hyperplasia. Moreover, it has been demonstrated that a pro-inflammatory stimulus such as tumor necrosis factor  $\alpha$  (TNF- $\alpha$ ) can stimulate the proliferation of adipocyte



precursors (Zubkova et al., 2016). Accordingly, precursors may be conditioned by the systemic inflammatory environment characteristic of CD, as previously described in other inflammatory-based diseases, including obesity, whereby an activation of the ASC niche occurs through an increase in ASC proliferative capacities (Pachon-Pena et al., 2016; Serena et al., 2016) and a decrease in their sensitivity to apoptosis (Ejarque et al., 2017).

Given this background, we hypothesized that CF associated with CD is the consequence of an elevated proliferation and migration capacity of ASCs of mesenteric AT to migrate to the inflamed intestine and, once there, differentiate to mature adipocytes. However, as the disease progresses the local pro-inflammatory environment might disturb ASC function. To investigate this, we characterized the biological and immunological properties of mesenteric ASCs isolated from patients with CD, both in clinical relapse and in clinical remission, including migration and invasion capacities and also phagocytic capacity. We extended this analysis to ASCs isolated from subcutaneous fat depots to test whether CD patients have a predisposition to greater activation of the immune system in a constitutional way that affects AT in general, without limitation in its location. Our work shows that CD alters the biological function and immune properties of ASCs as adipocyte precursors.

## RESULTS

### Mesenteric ASCs of Patients with CD Show Higher Proliferation Rates but Lower Adipogenic Capacities than Those of Healthy Donors

ASCs were isolated from visceral adipose tissue (VAT) of healthy subjects ( $n = 6$ ) and patients with active ( $n = 10$ ) or inactive ( $n = 5$ ) CD. When ASCs were isolated from the same amount of mesenteric AT from patients with CD (CD ASCs) and from healthy individuals (healthy ASCs), a greater number of ASCs was obtained from CD patients than from healthy individuals. Correspondingly, the AT-cell number ratio was significantly higher in CD ASCs, both from active and inactive patients, than in healthy ASCs (Figure 1A), which suggests an increase in the number of adipocyte precursors in mesenteric AT of CD patients. Moreover, 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) and 5-bromo-2'-deoxyuridine (BrdU) incorporation assays revealed a higher proliferation rate in mesenteric CD ASCs than in healthy ASCs (Figures 1B and 1C). To study the adipogenic potential of ASCs, we cultured them in well-defined adipogenic differentiation medium and evaluated lipid content and gene expression after 14 days. Neutral lipid content, measured by oil red O staining, was significantly lower in differentiated CD ASCs (independent of clinical stage) than in healthy


ASCs (Figures 1D and 1E), concomitant with a decrease in the gene expression of typical adipogenic markers such as *leptin*, *peroxisome proliferator activated receptor gamma* (*PPARG*), *fatty acid binding protein 4* (*FABP4*), and *lipoprotein lipase* (*LPL*) (Figure 1F). Collectively, these data reveal that similar to obesity (Pachon-Pena et al., 2016), CD modifies the plasticity of mesenteric ASCs.

### Mesenteric ASCs from Patients with CD Present an Inflammasome-Mediated Inflammatory Response

It is known that CF exhibits a high level of inflammatory cytokine secretion (Kredel and Siegmund, 2014). Consistent with this, we observed that gene expression of typical inflammatory markers (*IL6*, *TNFA*, *CCL2*, and *IL1B*) was higher in mesenteric CD ASCs from active patients than from healthy donors (Figure 2A). Of note, an inflammatory phenotype was also detected in CD ASCs from inactive patients (Figure 2A). As previously described for mesenteric AT of active CD patients (Zulian et al., 2012), the expression of anti-inflammatory markers such as *IL10* and *adiponectin* was also increased in CD ASCs (Figure 2A). Interestingly, expression of these markers was significantly lower in inactive CD ASCs than in active CD ASCs, revealing a decrease in anti-inflammatory mediators but not pro-inflammatory mediators in the former.

Because of the important role of interleukin-1 $\beta$  (IL-1 $\beta$ ) in host response (Grant and Dixit, 2013), we next examined inflammasome-mediated immune responses in ASCs. In accordance with the gene expression data, IL-1 $\beta$  protein expression in conditioned medium (CM) of ASCs was significantly higher in CD ASCs than in healthy ASCs, and was significantly higher in active CD ASCs than in inactive CD ASCs (Figure 2B). Gene expression levels of critical inflammasome components that drive IL-1 $\beta$  secretion (Grant and Dixit, 2013) were also measured in ASCs from healthy, inactive CD, and active CD subjects. In line with data on IL-1 $\beta$  secretion, gene expression of *NLRP1*, *NLRP3*, and *CASP1* was higher in mesenteric CD ASCs (both active and inactive) than in healthy ASCs. No significant differences in the gene expression of these inflammasome components were found between ASCs from active and inactive CD patients, with the exception of *NLRP1* (Figure 2C).

Given the close link between inflammasome activation and glucose homeostasis (Grant and Dixit, 2013; Serena et al., 2016), we compared the metabolic gene expression profile of ASCs isolated from CD patients and healthy controls ( $n = 4$  for all groups). Compared with healthy ASCs, both active and inactive CD ASCs displayed a glycolytic phenotype that was characterized by significantly higher expression of *SLC2A1*, *hexokinase-2* (*HK2*), *phosphofructokinase* (PFKM), and *lactate dehydrogenase-b* (*LDHB*), and significantly lower expression of *pyruvate dehydrogenase kinase-4*



### Figure 1. CD Increases Mesenteric ASC Proliferation and Reduces Their Adipogenic Differentiation Capacity

(A–C) AT-cell number ratio (A), MTT (B), and BrdU cell proliferation (C) assays were performed as detailed in [Experimental Procedures](#) to study the cell proliferation of mesenteric ASCs.

(D) Representative images of intracellular lipid enrichment in mature adipocyte (AD) from healthy subjects, active CD patients, and inactive CD individuals (magnification,  $\times 200$ ; scale bar, 200  $\mu\text{m}$ ).


(E) Quantification of oil red O staining of AD from healthy subjects, active CD patients, and inactive CD patients.

(F) Gene expression of adipogenic markers was analyzed by RT-PCR in AD and undifferentiated ASCs from healthy subjects, active CD patients, and inactive CD patients.  $n = 5$ –10 per group as explained in [Experimental Procedures](#).

\* $p < 0.017$  versus healthy ASCs; # $p < 0.017$  as indicated in the figure.

(*PDK4*) (Figure 2D). Interestingly, the level of *SLC2A4* mRNA was significantly lower in CD ASCs from active patients than from inactive patients (Figure 2D), presumably due to the greater systemic inflammation in the former (Papa et al., 1997; Poletto et al., 2015). The glycolytic phenotype of CD ASCs was accompanied by an increase in the amount of lactate and succinate released into CM ( $n = 4$  for all groups) (Figures 2E and 2F), which agreed

well with the detected lower and higher mRNA levels of *SDHB* and *OGDH*, respectively, in these cells (Figure 2D). CD ASCs also presented an increase in the expression of the  $\beta$ -oxidation markers *CPT1B* and *SLC25A2* (Figure 2D). Taken together, our data suggest that CD provokes glycolytic and fatty acid oxidation metabolism in mesenteric ASCs, as previously described in some tumor cells (Altundag et al., 2005). For all these experiments, ASCs were isolated



**Figure 2. CD Triggers an Inflammasome-Mediated Inflammatory Response in Mesenteric ASCs and Increases Their Metabolic Activity**

(A) Expression of *IL6*, *TNFA*, *CCL2*, *IL1B*, *IL10*, and *adiponectin* were analyzed by qPCR in ASCs isolated from VAT of healthy subjects, active CD patients, and inactive CD patients.

(B) Secretion of IL-1 $\beta$  was analyzed by ELISA from conditioned medium (CM) of ASCs from healthy subjects, active CD patients, and inactive CD patients.

(C) Gene expression of different components of the inflammasome, *NLRP1*, *NLRP3*, and *CASP1* were analyzed by qPCR.

(D) Gene expression of glucose and lipid metabolism genes was analyzed by qPCR in VAT ASCs.


(E and F) Lactate (E) and succinate (F) levels in CM of ASCs isolated from healthy subjects, active CD patients, and inactive CD patients. n = 5–10 per group as explained in [Experimental Procedures](#), with the exception of metabolic data (n = 4 for all groups). \*p < 0.017 versus healthy ASCs; #p < 0.017 as indicated in the figure.

from VAT of healthy subjects (n = 6), active CD patients (n = 10), and inactive CD patients (n = 5).

### Mesenteric ASCs from Patients with CD Have an Exacerbated Macrophage-like Phenotype

The inflammatory response, including immune cell migration, is essential both for host defense and tissue repair. We previously showed that ASCs can act as non-professional phagocytes, a capacity that is boosted in inflammatory settings such as obesity and type 2 diabetes (Serena et al., 2016). We used ASCs from VAT of healthy subjects (n = 6) and active (n = 10) and inactive (n = 5) CD patients for all experiments, with the exception of phagocyte data (n = 4

patients for all groups). We first evaluated ASC migration using Transwell assays. Remarkably, the 24-hr CM from explants of CF VAT of active CD patients triggered the strong migration of healthy ASCs, active CD ASCs, and also T Jurkat cells (Figure 3A), which agrees well with our hypothesis that ASCs migrate to CF. Furthermore, the basal migration of ASCs was significantly higher for CD ASCs, both from active and inactive patients, than for healthy ASCs (Figure 3B). We also examined the migration of monocytes (THP-1 cells), B lymphocytes (MEC-1 cells), and T lymphocytes (Jurkat cells) to ASC CM placed in the bottom chamber of the Transwell system, and detected that the migration of all cells was significantly greater to



### Figure 3. CD Changes the Functional Properties of Mesenteric ASCs

(A) The migratory capacity of healthy ASCs, active CD ASCs, and immune cells (Jurkat cells) into 24-hr CM of CF of active CD patients or VAT of healthy individuals were assessed in Transwell assays.

(B) The migratory capacity of basal ASCs isolated from VAT of healthy subjects, active CD patients, and inactive CD patients was assessed in Transwell assays. Representative toluidine blue-stained cells are shown below the graph (magnification,  $\times 200$ ; scale bar,  $200 \mu\text{m}$ ).

(C) CM of VAT from healthy subjects, active CD patients, and inactive CD patients was tested to ascertain if it promotes the migration of immune cells (monocytes, THP-1 cell line; B lymphocytes, MEC-1 cell line; and T lymphocytes, Jurkat cell line) using the Transwell system.

(D) Invasion capacity was studied in ASCs by adding Matrigel to the upper Transwell chamber. Representative toluidine blue-stained cells are shown below the graph (magnification,  $\times 200$ ; scale bar,  $200 \mu\text{m}$ ).

(E) Zymographic analysis of MMP2/9 activities using gelatin as substrate. Representative zymogram and densitometric analysis are shown.


(F) Phagocytosis assay was performed using a rhodamine-based red dye conjugated to *E. coli* bacteria, which turns bright red upon lysosomal acidification. Phagocytic activity of cells is marked in red and the cell nucleus is marked in blue (DAPI). Representative images of ASCs from healthy subjects, active CD patients, and inactive CD patients (magnification,  $\times 200$ ; scale bar,  $200 \mu\text{m}$ ).

(G) Phagocytosis was quantified using the Varioskan LUX multimode microplate reader. Fluorescence intensity was normalized to total protein content.

$n = 5-10$  per group as explained in [Experimental Procedures](#), with the exception of phagocytic data ( $n = 4$  for all groups). \* $p < 0.05$  versus healthy ASCs; # $p < 0.01$  as indicated in the figure.

CM generated from active CD ASCs than from healthy ASCs, whereas CM from inactive CD ASCs significantly stimulated the migration of B and T lymphocytes only and was moderately less effective than CD ASC CM in stimulating B cells (Figure 3C). Using Matrigel invasion assays, we found that CD ASCs exhibited a robust invasion capacity in basal non-stimulated conditions relative to healthy ASCs (Figure 3D). Consistent with the observed increase in cell migration/invasion, gene expression of two matrix metalloproteinase (MMP) family proteins, *MMP2* and *MMP9*, was significantly higher in CD ASCs than in healthy ASCs (Figure S1A) and correlated with increased *MMP2* and

*MMP9* activity measured by gelatin zymography (Figure 3E). We previously demonstrated that an inflammatory environment such as that found in obesity and type 2 diabetes increases ASC phagocytic capacity (Serena et al., 2016). Since cell migration and invasion are crucial steps for phagocytosis, we hypothesized that ASCs may respond to the bacterial translocation within mesenteric AT described in CD patients (Kruis et al., 2014) by increasing their phagocytic capacity. We therefore studied this parameter in CD ASCs and healthy ASCs. Remarkably, the phagocytic cell response against bacteria was significantly higher in CD ASCs than in healthy ASCs, as measured by the



**Figure 4. CD Alters the Functional Properties of Subcutaneous ASCs**

(A) Expression of *IL1B*, *IL6*, *TNFA* and *CCL2* was analyzed by qPCR in ASCs isolated from SAT of healthy subjects, active CD patients, and inactive CD patients.  
 (B) Secretion of IL-1 $\beta$  was analyzed by ELISA from CM of ASCs from healthy subjects, active CD patients, and inactive CD patients.  
 (C) Migratory capacity of ASCs isolated from healthy subjects, active CD patients, and inactive CD patients from SAT was assessed using the Transwell system.

(legend continued on next page)



ingestion of pHrodo-labeled *Escherichia coli* BioParticles (Figures 3F and 3G). In line with this finding, gene expression of the typical phagocytic/endocytosis markers *RAB7A* and *RAB5A* was significantly higher in CD ASCs than in healthy ASCs (Figure S1B). Of note, neither CD ASCs nor healthy ASCs were able to phagocytose yeast (data not shown), indicating specific phagocytic capabilities for ASCs. Collectively, these data indicate that mesenteric ASCs isolated from CD patients are immune activated, even when the disease is in clinical remission.

### ASCs Isolated from Subcutaneous Fat Depots of Patients with CD Also Show an Activation of the Immune Response

To determine whether the pro-inflammatory effects of CD on ASCs was restricted to visceral fat depots or was a global response, we next examined ASCs isolated from subcutaneous adipose tissue (SAT) depots. We used ASCs from SAT of healthy subjects ( $n = 6$ ), active CD patients ( $n = 10$ ), and inactive CD patients ( $n = 6$ ) for all experiments, with the exception of phagocyte data ( $n = 4$  patients for all groups). We found that ASCs from SAT, both from active and inactive CD patients, largely recapitulated the phenotype of equivalent VAT-derived ASCs, including a significantly higher AT-cell number ratio and proliferative activity (Figures S2A and 2B), and a reduced adipogenic differentiation capacity (Figures S2C and 2D) compared with their healthy counterparts. Moreover, gene expression of inflammatory markers (*IL1B*, *IL6*, *TNFA*, and *CCL2*) was significantly higher in ASCs isolated from SAT of active and inactive CD patients than in cells from healthy donors (Figure 4A). Also, the secretion of IL-1 $\beta$  into CM was significantly higher for CD ASCs than for healthy ASCs (Figure 4B). Overall, these results indicate that ASCs from SAT of CD patients exhibit an inflammatory profile, even during clinical remission of the disease.

The migratory properties of SAT-derived ASCs from patients with CD also mirrored those of VAT-derived ASCs with respect to basal migration (Figure 4C), migration of monocytes and B and T lymphocytes to CM (Figure 4D),

invasion (Figure 4E), and gene expression of *MMP2/9* (Figure 4F). However, contrasting with the results for VAT-derived ASCs, only active CD ASCs showed a significantly higher phagocytic capacity than their healthy counterparts (Figures 4G and 4H), which was accompanied by significantly higher expression of *RAB7A* and *RAB5A* (Figure 4I). Collectively, these findings indicate that while the inflammatory response is also activated in ASCs from the SAT of patients with CD, only those from active CD present a phagocyte-like phenotype.

### Loss of Immunosuppressive Properties in SAT ASCs from Patients with CD

We next explored whether ASCs isolated from SAT of patients with CD retain their typical immunoregulatory properties (Melief et al., 2013). We previously demonstrated that protective immunosuppressive properties, including elevated TGF- $\beta$ 1 secretion, promotion of M2 macrophage polarization, and inhibition of T and B cell proliferation, all of which are mainly ascribed to SAT-derived ASCs, are perturbed in ASCs isolated from an obesity-induced inflammatory milieu (Serena et al., 2016). Similar to that observed in obesity, *TGFB1* expression was lower both in active ( $n = 10$ ) and inactive ( $n = 6$ ) CD ASCs than in healthy ASCs ( $n = 6$ ), and this was significant for levels both in inactive and active CD ASCs (Figure 5A). Moreover, the level of TGF- $\beta$ 1 protein in CM was significantly lower from inactive CD ASCs than from healthy ASCs (Figure 5B). We also observed that the capacity to promote the M2 macrophage phenotype was blunted in ASCs isolated from CD patients. Accordingly, human THP1 PMA-activated macrophages (M0) were incubated with CM from healthy, active CD, and inactive CD ASCs ( $n = 6$ – $10$  for all groups), and gene expression of typical M2 markers was quantified. Whereas expression of *IL10*, *CD163*, and *MRC1* in THP1 cells was significantly increased after addition of CM from healthy ASCs, this increase was less evident when M0 macrophages were cultured with CM from inactive or active CD ASCs (Figure 5C). We also analyzed the expression of M1 markers and found that CM of healthy ASCs, but not of CD ASCs,

(D) CM of SAT from healthy subjects, active CD patients, and inactive CD patients was tested to ascertain if it promotes the migration of immune cells (monocytes, THP-1 cell line; B lymphocytes, MEC-1 cell line; and T lymphocytes, Jurkat cell line) using the Transwell system.

(E) Invasion capacity was studied in ASCs by adding Matrigel to the upper Transwell chamber.


(F) *MMP2* and *MMP9* gene expression was analyzed by qPCR in ASCs from healthy subjects, active CD patients, and inactive CD patients.

(G) Phagocytosis assay was performed using a rhodamine-based red dye conjugated to *E. coli* bacteria, which turns bright red upon lysosomal acidification. Phagocytic activity of cells is marked in red, and the cell nucleus is marked in blue (DAPI). Representative images of ASCs from healthy subjects, active CD patients, and inactive CD patients (magnification,  $\times 200$ ; scale bar, 200  $\mu$ m).

(H) Phagocytosis was quantified using the Varioskan LUX multimode microplate reader. Fluorescence intensity was normalized to total protein content.

(I) Gene expression of different phagocytic markers, *LAMP1*, *RAB5A*, and *RAB7A*, was analyzed by qPCR.

$n = 6$ – $10$  per group as explained in Experimental Procedures, with the exception of phagocytic data ( $n = 4$  for all groups). \* $p < 0.017$  versus healthy ASCs; # $p < 0.017$  as indicated in the figure.



**Figure 5. CD Reduces the Immunosuppressive Properties of ASCs**

(A) ASCs were isolated from SAT of healthy subjects, active CD patients, and inactive CD patients, and the expression of *TGFB1* was analyzed by qPCR. (B) Secretion of TGF- $\beta$ 1 was analyzed by ELISA in CM of ASCs from healthy subjects, active CD patients, and inactive CD patients. (C) CM of ASCs from SAT of healthy subjects, active CD patients, and inactive CD patients, was added to THP-1 PMA-activated macrophage, and gene expression of M1/M2 phenotype markers was analyzed by qPCR. (D) Cell proliferation of Jurkat T cells and MEC-1 B cells was measured after adding CM of ASCs from SAT of healthy subjects, active CD patients, and inactive CD patients.

(legend continued on next page)



significantly decreased the expression of a panel of M1 markers (Figure 5C). We next evaluated the capacity of ASCs to inhibit T and B cell proliferation. Whereas CM from healthy ASCs suppressed the proliferation of T and B cells, CM from CD ASCs had the opposite effect and significantly increased T and B cell proliferation (Figure 5D). Our results show that the typical immunosuppressive properties of ASCs are blunted in CD patients.

To further examine the inflammatory capacity of ASCs, we performed co-culture experiments with naive T lymphocytes. We found that naive T lymphocytes that were co-cultured with active CD ASCs presented a significant increase in the gene expression of the T helper cell 1 (Th1) marker *TNFA*, and a significant decrease of the Th2 marker *GATA3* and of the regulatory T cell (Treg) marker (*TGFB1*), compared with those co-cultured with healthy ASCs (Figure 5E). Remarkably, when we studied the secretion of soluble factors, the amount of granulocyte colony-stimulating factor (G-CSF) was significantly lower in the supernatant of naive T lymphocytes co-cultured with active CD ASCs than with healthy ASCs (Figure 5F). It is known that G-CSF mediates immune regulation, including the ability to promote Treg differentiation and has beneficial effects in the prevention of inflammatory bowel diseases in animal models (Rutella et al., 2005). Finally, we separated ASCs and naive T lymphocytes after 48 hr of co-culture and analyzed gene expression of *GCSF* in the two cell types by qPCR. We found that *G-CSF* expression was significantly lower in active CD ASCs than in healthy ASCs (Figure 5G). This result strongly suggests that healthy ASCs may produce G-CSF, which promotes Treg differentiation (Rutella et al., 2005). Conversely, the lower gene expression and production of G-CSF in active CD ASCs co-cultured with naive T cells may lead to a decrease Treg differentiation. Thus, the co-culture between naive T cells and ASCs is necessary to secrete G-CSF. Accordingly, CD ASCs in contact with naive T lymphocytes *in vivo* may lead to a change in the phenotype of these cells in CD patients and decrease the T regulatory lymphocyte population.

### Inflammasome Inhibition Counters the Invasive and Glycolytic Phenotype of ASCs from CD Patients

Both TGF- $\beta$ 1 and IL-1 $\beta$  have been previously revealed as key players in the dysfunctional behavior of ASCs in metabolic diseases linked to inflammation (Barbagallo et al., 2017; Pourgholaminejad et al., 2016; Serena et al.,

2016). We therefore attempted to reverse the phenotype of ASCs isolated from CD patients using different strategies to inhibit inflammasome components. To do this, we treated ASCs ( $n = 4$  for all groups) with the IL-1 receptor antagonist (IL1RA), the caspase-1 inhibitor YVAD-CHO, or TGF- $\beta$ 1, alone or in combination. Only combined treatment of IL1RA plus YVAD-CHO was effective in significantly reducing the invasion capacity of ASCs isolated from the SAT and mesenteric AT depots of active and inactive CD patients (Figures 6A and 6B), which was accompanied by a significant reduction of *MMP2/9* gene expression (Figures 6C and 6D). Moreover, this combination resulted in a decrease in the gene expression of inflammatory and inflammasome markers and also phagocyte markers (Figures 6E and 6F). Surprisingly, the combined treatment of IL1RA plus YVAD-CHO reversed the effects of the CD environment on glycolytic but not  $\beta$ -oxidation markers (Figures 6E and 6F), suggesting that the inflammasome directs the invasive and glycolytic phenotype of ASCs in the context of CD.

## DISCUSSION

CD is a complex multifactorial inflammatory disorder. AT is an important source of immune-competent cells, including ASCs. Here we show that mesenteric CF contains ASCs with highly proliferative and invasive capacities and an altered immune profile. Remarkably, most of the features of ASCs from patients with an active stage of the disease are also observed in patients with clinical remission, both in mesenteric and subcutaneous depots.


CF is traditionally viewed as an unusual growth of mesenteric AT that secretes pro-inflammatory cytokines, chemokines, and acute phase proteins; however, whether it is a contributor to chronic inflammation, an initiator, or simply a bystander remains unknown. To date, no studies have focused on ASCs as active immune-competent cells in CD. We show that ASCs both from mesenteric CF and subcutaneous fat have an activated inflammasome. Classically, inflammasome-driven caspase-1 activation and IL-1 $\beta$  secretion occur as an innate immune response to protect the host against pathogens (Carracedo et al., 2013). In addition to this pro-inflammatory response, we found that ASCs isolated from the CF of CD patients have higher gene expression levels of anti-inflammatory

(E) Gene expression of Th1/Th2/Treg markers were studied in naive T lymphocytes that were co-cultured with healthy or active CD ASCs for 48 hr.

(F) Secretion of G-CSF was analyzed by ELISA in culture supernatant of co-cultured naive T lymphocytes with healthy ASCs or active CD ASCs.

(G) Gene expression of *GCSF* in ASCs previously co-cultured with naive T lymphocytes.

$n = 6-10$  per group. \* $p < 0.017$  versus healthy ASCs; # $p < 0.017$  versus control (CM) as indicated in the figure.



**Figure 6. Inflammation Inhibition of CD ASCs Reverses the Immune-Activated Phenotype**

(A–D) Invasion capacity was studied in (A) SAT or (B) VAT CD ASCs treated with 40 ng/mL interleukin 1 receptor antagonist (IL1RA), 20 ng/mL TGF- $\beta$ 1, 10  $\mu$ M YVAD-CHO (caspase-1 inhibitor), or the combined treatments at the same doses described in the figure. *MMP2/9*

(legend continued on next page)



molecules such as *adiponectin* or *IL-10* than those isolated from VAT of healthy individuals. These data seem contradictory, but are in agreement with previous data from [Yamamoto et al. \(2005\)](#) who demonstrated that adiponectin production is higher in hyperplastic mesenteric AT contiguous with the involved intestine of CD patients than in healthy mesenteric AT. Indeed, the authors suggest that adiponectin secretion by mesenteric adipocytes could negatively regulate some of the inflammatory reactions observed in CD. We speculate that this may be due in part to the small size of adipocytes in the CF, as it has recently been shown that adiponectin secretion correlates negatively with adipocyte size ([Meyer et al., 2013](#)). Accordingly, the small adipocytes characteristic of CF of CD patients may secrete higher amounts of adiponectin. In line with inflammasome activation ([Grant and Dixit, 2013](#); [Serena et al., 2016](#)), CD ASCs showed a strong glycolytic metabolic phenotype, presumably due to high metabolic demand for ATP to maintain their proliferative, migratory, and invasive capacities, akin to the Warburg effect in cancer cells. Moreover, the  $\beta$ -oxidation markers CPT1B and SLC25A2 are increased in CD ASCs. We hazard that this increase in oxidative metabolism reflects their proliferative activity, as *de novo* synthesis of fatty acids is required to maintain cellular membrane synthesis in a manner similar to what has been recently described in certain tumor cells ([Carra-cedo et al., 2013](#)).

Of particular interest was our finding that subcutaneous ASCs from patients with CD present an elevated inflammatory threshold despite residing beyond the inflamed AT compartment, and this is also seen in patients in clinical remission of the disease. Previous studies have reported that the SAT of patients with CD in clinical remission is completely free from the disease, with a gene expression and inflammatory cytokine secretion profile similar to that found in SAT of healthy individuals ([Zulian et al., 2012](#)). While our data show that ASCs isolated from CD SAT have an inflammatory phenotype, we believe that these results are not contradictory. We speculate that these differences may be attributable to the cellular plasticity of AT resident cells, specifically macrophages, which can modify their functional phenotype depending on environmental cues ([Leavy, 2011](#)). Indeed, adipose tissue macrophages (ATMs) and monocytes derived from peripheral blood mononuclear cells are highly plastic in CD, as shown by the dramatic decrease in the expression of inflammatory markers once the disease is in clinical remis-

sion ([Figure S3](#)). Nevertheless, we found that ASCs from inactive CD patients remained primed to immunomodulatory dysfunction as evidenced by the largely similar phenotype to that found in active CD ASCs, indicating that ASCs are not equally as plastic as ATMs and maintain an altered functionality. Thus, inflammation induces irreversible changes to CD ASCs, shifting them toward an inflammatory profile even in periods of clinical disease remission.

We found that ASCs from patients with CD had a robust invasion capacity and bacterial phagocytic activity, pointing to a role for these cells in the inflammatory events occurring in damaged intestinal tissue. We hypothesize that upon microbial dysregulation, a hallmark of CD, ASCs migrate from mesenteric AT and specifically home to intestinal lesions. This event, which would be beneficial initially, also induces an accumulation of AT CF surrounding the intestine, which is a consequence of the natural fate of ASCs to differentiate into adipocytes. Furthermore, our data suggest that the hyperplasia of adipocytes observed in the CF of CD patients could potentially be a result of the ASCs inherent to this compartment, and not from other adipose depots.

A limitation to our study is the potential confounding effects that may have been caused by systemic steroid therapy, mainly in the active disease cohort ([Table 1](#)). One would expect a decrease in the immune response because of the immunosuppressant properties of corticosteroids; however, we found that the immune response of ASCs from these patients was clearly increased in parallel with markers of disease activity, suggesting little or no effect associated with systemic steroid treatment.

ASCs are considered as regenerative cells that promote tissue repair and regeneration *in vivo* ([Baptista et al., 2015](#)). In the present study we demonstrate that, similar to what is observed in obesity ([Serena et al., 2016](#)), ASCs of CD patients are immune activated, are inhibited in their adipogenic differentiation potential, and have dampened immunosuppressive properties. This persistent immune activation in patients may help to explain that while autologous transplants may be effective, they do not always prevent relapse or improve the disease outcome. Moreover, a recent report on allogeneic ASC transplantation reported an efficacy of 26% ([Panés et al., 2016](#)), which might be due to the metabolic phenotype of the donor. Our data offer a new perspective to better interpret the discrepancies

---

gene expression was analyzed by qPCR in ASCs from (C) SAT and (D) VAT isolated from healthy subjects, active CD patients, and inactive CD patients.

(E and F) SAT (E) and VAT (F) relative gene expression of inflammasome, phagocytic, and metabolic markers was determined in untreated CD ASCs (basal) or those treated with IL1RA plus YVAD-CHO.

n = 4 for all groups. \*p < 0.017 versus untreated ASCs (basal); #p < 0.017 as indicated in the figure.

**Table 1. Anthropometric and Biochemical Variables from the Cohort**

	Healthy	Inactive CD	Active CD
n (SAT/VAT)	6/6	6/5	10/10
Sex (male/female)	3/3	3/3	5/5
Age (years)	43 ± 8.2	41.2 ± 5.4	39.8 ± 12.4
BMI (kg/m <sup>2</sup> )	23.15 ± 2.1	24.59 ± 3.3	23.2 ± 3.8
Glucose (mg/dL)	81.1 ± 4.9	87 ± 12.5	72 ± 9.7
Cholesterol (mg/dL)	105 ± 17.3	131 ± 23.4	150 ± 20.3 <sup>a</sup>
HDLc (mg/dL)	38.9 ± 4.6	46.6 ± 4.2 <sup>a</sup>	42.9 ± 5.4
Triglycerides (mg/dL)	100 ± 5.3	116 ± 13.1 <sup>a</sup>	96 ± 9.9
Insulin (μIU/mL)	2.07 ± 0.9	5.25 ± 1.2 <sup>a</sup>	7.5 ± 1.4 <sup>a,b</sup>
HOMA-IR	0.49 ± 0.1	1.2 ± 0.5	1.45 ± 0.35 <sup>a</sup>
Age at diagnosis (years)	–	38 ± 8.6	28.5 ± 9.4
Last attack (months)	–	24 ± 15.7	–
Indication for surgery	CoH	CoH	5 SCD/5 FCD
Preoperative immunomodulator use	–	6/6	10/10
Preoperative biological agent treatment	–	0/6	0/10
Preoperative steroid treatment	–	3/6	8/10
C-reactive protein (mg/dL)	0.1 ± 0.09	0.39 ± 0.15	6.14 ± 3.81 <sup>a,b</sup>

SAT, subcutaneous adipose tissue; VAT, visceral adipose tissue; BMI, body mass index; HDLc, high-density lipoprotein cholesterol; CoH, cholecystectomy or hernia; SCD, stenotic Crohn’s disease; FCD, fistulizing Crohn’s disease.

Results are presented as mean ± SD. ANOVA followed by post hoc Bonferroni test was used to compare means between groups.

<sup>a</sup>p < 0.01 versus healthy.

<sup>b</sup>p < 0.05 versus inactive CD.

in clinical assays using ASCs in patients with CD. We propose that ASCs with the best immunomodulatory properties should be chosen, or/and alternatively treated *ex vivo* to restore their immunosuppressive properties (as shown here with an IL-1β antagonist), before their use in cell therapy both for autologous and allogeneic transplantation. This information may be important for clinical trial design. Clinicians should be aware of possible autologous cell transplant contraindications (reduced anti-inflammatory properties of ASCs in CD patients, including those in remission) and select the best donor regarding also the metabolic phenotype if an allogeneic cell transplant is chosen. While further studies are necessary to fully characterize the molecular events leading to immune activation of resident ASCs, the results shown here highlight their importance in CD and support their role in the formation of creeping fat. Moreover, our findings indicate a path for increasing the therapeutic benefit of stem cell transplantation in CD. Future studies in animal models will be needed to

demonstrate *in vivo* the reduced anti-inflammatory properties associated with CD ASCs.

## EXPERIMENTAL PROCEDURES

### Study Subjects

Subjects were recruited at the University Hospital Joan XXIII (Tarragona, Spain) and University Hospital Vall d’Hebrón (Barcelona, Spain) in accordance with the tenets of the Helsinki Declaration. The corresponding hospital ethics committees approved the study, and written informed consent was obtained from all participants before entering in the study. Donors were classified as those in relapse (active) or in remission (inactive) following the Crohn’s Disease Activity Index criteria (Best et al., 1976; Van Assche et al., 2010). Healthy subjects (n = 6) and inactive CD donors (n = 6) were recruited from age- and gender-matched subjects undergoing non-acute surgical interventions such as hernia or cholecystectomy, in a scheduled routine surgery. Active CD patients (n = 10) were recruited from those undergoing surgery for symptomatic



complications. VAT from mesenteric origin and SAT were obtained from the same individual during the surgical procedure, with the exception of one inactive CD patient, in which only SAT was available. Clinical data, anthropometric, and biochemical variables from the cohort are presented in [Table 1](#).

### ASC Isolation and Culture

ASCs were isolated as described previously ([Dubois et al., 2008](#); [Gimble and Guilak, 2003](#)). In brief, SAT and VAT was washed extensively with PBS to remove debris and treated with 0.1% collagenase in PBS and 1% BSA for 1 hr at 37°C with gentle agitation. Digested samples were centrifuged at  $300 \times g$  at 4°C for 5 min to separate adipocytes from stromal cells. The cell pellet containing the stromal fraction was resuspended in stromal culture medium consisting of DMEM/F12, 10% fetal bovine serum (FBS), and 1% antibiotic/antimycotic solution. To prevent spontaneous differentiation, primary cultures of ASCs at passage 0 (P0) were grown to 90% confluence and harvested with trypsin-EDTA, and aliquots ( $1 \times 10^6$  cells) were cryopreserved in liquid nitrogen until required ([Pachon-Pena et al., 2011](#)). ATMs were also isolated from the stromal vascular fraction of AT biopsies as described previously ([Ceperuelo-Mallafre et al., 2016](#); [Serena et al., 2016](#); [Titos et al., 2011](#)). The AT-cell number ratio was defined as the ratio of the number of cells proliferating at P0 per gram of AT digested.

### Human ASC Immunophenotyping

ASCs ( $2 \times 10^5$  cells) were incubated with a panel of primary antibodies described in [Table S1](#) ([Pachon-Pena et al., 2016](#)). After isolation, the minimal functional and quantitative criteria, established by the International Society of Cell Therapy and the International Federation for Adipose Therapeutics and Science, were routinely confirmed by flow cytometry as described previously ([Pachon-Pena et al., 2016](#); [Serena et al., 2016](#)). All experiments were performed in cells at P3–P7.

### Cell Migration Assay

Basal migratory capacity of ASCs was analyzed using a Transwell system (8- $\mu$ m pore polycarbonate membrane) as described previously ([Baek et al., 2011](#); [Corcione et al., 2006](#); [Serena et al., 2016](#)). The migratory capacity of human monocytes (THP-1 cell line) and T and B lymphocytes (Jurkat and MEC-1 cells, respectively) in response to application of 24-hr CM from undifferentiated ASCs was performed using 5- $\mu$ m pore polycarbonate Transwell inserts as described by [Serena et al. \(2016\)](#). A similar experiment was performed to examine the migratory capacity of ASCs and T cells (Jurkat) in response to 24-hr CM from VAT explants of active (CF origin) and from healthy individuals (mesenteric origin).

### Cell Invasion Assay

Invasion capacity was determined as for migration except that the membrane was first coated with Matrigel (Sigma, St. Louis, MO, USA) in PBS for 2 hr at 37°C. ASCs were added to the upper chamber and incubated for 24 hr at 37°C. Cells invading the lower surface of the Transwell membrane were stained and counted.

### Zymography

To determine MMP-2 and MMP-9 activity, near-confluent ASCs (80%) were deprived of serum for 24 hr and the CM was electrophoresed in 8% SDS-polyacrylamide gels polymerized with 0.1% gelatin under non-reducing conditions. Gels were washed with 2.5% Triton X-100 (30 min) to remove SDS, rinsed with substrate buffer (0.2 M NaCl, 5 mM CaCl<sub>2</sub>, 1% Triton X-100, 0.02% NaN<sub>3</sub>, 50 mM Tris [pH 7.5]) and incubated in this buffer at 37°C overnight to allow protein renaturation and MMP activation. Gels were stained with Coomassie brilliant blue (Bio-Rad, Richmond CA, USA) to visualize gelatin degradation.

### Phagocytosis Assay

The pHrodo *Escherichia coli* (bacteria) and *Zymosan* (yeast) Bio-Particles Phagocytosis Kits (Invitrogen Molecular Probes, Eugene, OR, USA) were used to assess the phagocytic capacity of undifferentiated ASCs (seeded at a density of 20,000 cells/cm<sup>2</sup>). Phagocytic activity was quantified using the Varioskan LUX multimode microplate reader (Thermo Fisher Scientific, Waltham, MA, USA).

### Cell Proliferation Assays

#### MTT Assay

Cell proliferation was determined by a standard colorimetric MTT assay. In brief, ASCs were seeded in 96-well plates and allowed to attach for 24 hr; after which the MTT assay (day +1) was performed to count the initial number of cells. After 7 days, a second MTT assay was performed (day +7), and the difference in absorbance between day +7 and day +1 was considered the proliferation of the ASCs.

#### BrdU Assay

ASC proliferation was also assessed by incorporation of BrdU using the BrdU Cell Proliferation Assay Kit (Millipore, Billerica, MA, USA). Cells (10,000/well) were cultured in 96-well plates containing DMEM/F12 medium with 10% (v/v) FBS at 37°C in 5% CO<sub>2</sub> and allowed to attach for 24 hr. BrdU was added to the medium and cells were incubated for a further 18 hr. Cells were then fixed, and BrdU incorporation was determined with an anti-BrdU specific antibody with detection by spectrophotometry at 450 nm. Proliferation of Jurkat and MEC-1 cells in response to CM from ASCs was performed in the same manner.

### Co-culture of Naive T Lymphocytes and ASCs

Co-culture experiments between human naive T lymphocytes and ASCs isolated from healthy subjects or CD patients were performed to measure T cell responses. In brief, 60,000 ASCs/well from healthy or active CD patients were seeded in 12-well plates and allowed to attach overnight; after which 800,000 T cells/well were added. After 48 hr, the supernatant was collected to determine T cell subsets (Th1/Th2/Treg) using the Multi-analyte ELISA Array Kit, MEH:003A (Qiagen, Germany), and the gene expression of T cells subset markers were assessed by qPCR.

### Statistical Analysis

For *in vitro* data, experimental results are presented as mean  $\pm$  SD from 4–10 independent experiments (independent donors) performed at least in duplicate. Comparisons among the three groups



were performed using the non-parametric Kruskal-Wallis test and between two groups using the Mann-Whitney U test with Bonferroni adjustment (significance,  $p < 0.017$ ). For clinical and anthropometrical variables, normally distributed data are expressed as mean  $\pm$  SD and for variables with no Gaussian distribution, values are expressed as median (interquartile range). Statistical analysis was performed with the Statistical Package for the Social Sciences software, version 15 (SPSS, Chicago, IL, USA). For details of further experiments, see [Supplemental Experimental Procedures](#).

## SUPPLEMENTAL INFORMATION

Supplemental Information includes Supplemental Experimental Procedures, three figures, and two tables and can be found with this article online at <http://dx.doi.org/10.1016/j.stemcr.2017.07.014>.

## AUTHOR CONTRIBUTIONS

C.S., N.K., A.M., E.M.-M., M.E., and M.T.-P. carried out the experiments and generated data. E.E., M. Martí, N.B., F.G., M. Menacho, and M. Millan carried out part of the study selection and human sample processing. A.Z., M. Millan, and S.F.-V. contributed to the discussion and reviewed the manuscript. C.S. and J.V. conceived the study, discussed data, and wrote the manuscript, and are the guarantors of this work. N.K. and A.M. contributed equally.

## ACKNOWLEDGMENTS

This study was supported by grants from the Spanish Ministry of Economy and Competitiveness (MINECO) and Instituto de Salud Carlos III (PI15/00143 to C.S.; PIE14/00045 (Inflammas), PI14/00228, and CB07708/0012 to J.V.; and SAF2015-65019-R to S.F.-V.) and a unrestricted grant supported by Menarini Lab SA. C.S. acknowledges support from the “Ramón y Cajal” program from MINECO (RYC2013-13186), and S.F.-V. from the Miguel Servet tenure-track program (CPII16/00008) from the Fondo de Investigación Sanitaria. A.M. acknowledges support from MINECO (FJCI-2014-23060). All were co-financed by the European Regional Development Fund. The authors thank Kelly Roche and Cati Nuñez for excellent technical assistance and Dr. McCreath for helpful comments on the manuscript.

Received: February 8, 2017

Revised: July 18, 2017

Accepted: July 18, 2017

Published: September 28, 2017

## REFERENCES

Altundag, K., Altundag, O., Baptista, M.Z., and Akyurek, S. (2005). Heparanase activity and bone loss in postmenopausal breast cancer patients. *J. Clin. Oncol.* *23*, 8916–8917, author reply 8917–8918.

Baek, S.J., Kang, S.K., and Ra, J.C. (2011). In vitro migration capacity of human adipose tissue-derived mesenchymal stem cells reflects their expression of receptors for chemokines and growth factors. *Exp. Mol. Med.* *43*, 596–603.

Baptista, L.S., Silva, K.R., and Borojevic, R. (2015). Obesity and weight loss could alter the properties of adipose stem cells? *World J. Stem Cells* *7*, 165–173.

Barbagallo, I., Li Volti, G., Galvano, F., Tettamanti, G., Pluchinotta, F.R., Bergante, S., and Vanella, L. (2017). Diabetic human adipose tissue-derived mesenchymal stem cells fail to differentiate in functional adipocytes. *Exp. Biol. Med. (Maywood)* *242*, 1079–1085.

Batra, A., Heimesaat, M.M., Bereswill, S., Fischer, A., Glauben, R., Kunkel, D., Scheffold, A., Erben, U., Kuhl, A., Loddenkemper, C., et al. (2012). Mesenteric fat - control site for bacterial translocation in colitis? *Mucosal Immunol.* *5*, 580–591.

Best, W.R., Beckett, J.M., Singleton, J.W., and Kern, F., Jr. (1976). Development of a Crohn's disease activity index. National Cooperative Crohn's Disease Study. *Gastroenterology* *70*, 439–444.

Buning, C., von Kraft, C., Hermsdorf, M., Gentz, E., Wirth, E.K., Valentini, L., and Haas, V. (2015). Visceral adipose tissue in patients with Crohn's disease correlates with disease activity, inflammatory markers, and outcome. *Inflamm. Bowel Dis.* *21*, 2590–2597.

Carracedo, A., Cantley, L.C., and Pandolfi, P.P. (2013). Cancer metabolism: fatty acid oxidation in the limelight. *Nat. Rev. Cancer* *13*, 227–232.

Ceperuelo-Mallafre, V., Ejarque, M., Serena, C., Duran, X., Montori-Grau, M., Rodriguez, M.A., Yanes, O., Nunez-Roa, C., Roche, K., Puthanveetil, P., et al. (2016). Adipose tissue glycogen accumulation is associated with obesity-linked inflammation in humans. *Mol. Metab.* *5*, 5–18.

Coffey, J.C., and O'Leary, D.P. (2016). The mesentery: structure, function, and role in disease. *Lancet Gastroenterol. Hepatol.* *1*, 238–247.

Connelly, T.M., Juza, R.M., Sangster, W., Sehgal, R., Tappouni, R.F., and Messaris, E. (2014). Volumetric fat ratio and not body mass index is predictive of ileocectomy outcomes in Crohn's disease patients. *Dig. Surg.* *31*, 219–224.

Corcione, A., Benvenuto, F., Ferretti, E., Giunti, D., Cappiello, V., Cazzanti, F., Riso, M., Gualandi, F., Mancardi, G.L., Pistoia, V., et al. (2006). Human mesenchymal stem cells modulate B-cell functions. *Blood* *107*, 367–372.

Desreumaux, P., Ernst, O., Geboes, K., Gambiez, L., Berrebi, D., Muller-Alouf, H., Hafraoui, S., Emilie, D., Ectors, N., Peuchmaur, M., et al. (1999). Inflammatory alterations in mesenteric adipose tissue in Crohn's disease. *Gastroenterology* *117*, 73–81.

Dubois, S.G., Floyd, E.Z., Zvonic, S., Kilroy, G., Wu, X., Carling, S., Halvorsen, Y.D., Ravussin, E., and Gimble, J.M. (2008). Isolation of human adipose-derived stem cells from biopsies and liposuction specimens. *Methods Mol. Biol.* *449*, 69–79.

Ejarque, M., Ceperuelo-Mallafre, V., Serena, C., Pachon, G., Nunez-Alvarez, Y., Terron-Puig, M., Calvo, E., Nunez-Roa, C., Oliva-Olivera, W., Tinahones, F.J., et al. (2017). Survivin, a key player in cancer progression, increases in obesity and protects adipose tissue stem cells from apoptosis. *Cell Death Dis.* *8*, e2802.

Fink, C., Karagiannides, I., Bakirtzi, K., and Pothoulakis, C. (2012). Adipose tissue and inflammatory bowel disease pathogenesis. *Inflamm. Bowel Dis.* *18*, 1550–1557.





- Gimble, J., and Guilak, F. (2003). Adipose-derived adult stem cells: isolation, characterization, and differentiation potential. *Cytotherapy* 5, 362–369.
- Goncalves, P., Magro, F., and Martel, F. (2015). Metabolic inflammation in inflammatory bowel disease: crosstalk between adipose tissue and bowel. *Inflamm. Bowel Dis.* 21, 453–467.
- Grant, R.W., and Dixit, V.D. (2013). Mechanisms of disease: inflammasome activation and the development of type 2 diabetes. *Front. Immunol.* 4, 50.
- Kappelman, M.D., Rifas-Shiman, S.L., Porter, C.Q., Ollendorf, D.A., Sandler, R.S., Galanko, J.A., and Finkelstein, J.A. (2008). Direct health care costs of Crohn's disease and ulcerative colitis in US children and adults. *Gastroenterology* 135, 1907–1913.
- Kredel, L.I., and Siegmund, B. (2014). Adipose-tissue and intestinal inflammation—visceral obesity and creeping fat. *Front. Immunol.* 5, 462.
- Kruis, T., Batra, A., and Siegmund, B. (2014). Bacterial translocation—impact on the adipocyte compartment. *Front. Immunol.* 4, 510.
- Leavy, O. (2011). Immunotherapy: stopping monocytes in their tracks. *Nat. Rev. Immunol.* 11, 715.
- Li, Y., Zhu, W., Gong, J., Zhang, W., Gu, L., Guo, Z., Cao, L., Shen, B., Li, N., and Li, J. (2015). Visceral fat area is associated with a high risk for early postoperative recurrence in Crohn's disease. *Colorectal Dis.* 17, 225–234.
- Melief, S.M., Schrama, E., Brugman, M.H., Tiemessen, M.M., Hoogduijn, M.J., Fibbe, W.E., and Roelofs, H. (2013). Multipotent stromal cells induce human regulatory T cells through a novel pathway involving skewing of monocytes toward anti-inflammatory macrophages. *Stem Cells* 31, 1980–1991.
- Meyer, L.K., Ciaraldi, T.P., Henry, R.R., Wittgrove, A.C., and Phillips, S.A. (2013). Adipose tissue depot and cell size dependency of adiponectin synthesis and secretion in human obesity. *Adipocyte* 2, 217–226.
- Pachon-Pena, G., Yu, G., Tucker, A., Wu, X., Vendrell, J., Bunnell, B.A., and Gimble, J.M. (2011). Stromal stem cells from adipose tissue and bone marrow of age-matched female donors display distinct immunophenotypic profiles. *J. Cell. Physiol.* 226, 843–851.
- Pachon-Pena, G., Serena, C., Ejarque, M., Petriz, J., Duran, X., Oliva-Olivera, W., Simo, R., Tinahones, F.J., Fernandez-Veledo, S., and Vendrell, J. (2016). Obesity determines the immunophenotypic profile and functional characteristics of human mesenchymal stem cells from adipose tissue. *Stem Cells Transl. Med.* 5, 464–475.
- Panes, J., Garcia-Olmo, D., Van Assche, G., Colombel, J.F., Reinisch, W., Baumgart, D.C., Dignass, A., Nachury, M., Ferrante, M., Kazemi-Shirazi, L., et al. (2016). Expanded allogeneic adipose-derived mesenchymal stem cells (Cx601) for complex perianal fistulas in Crohn's disease: a phase 3 randomised, double-blind controlled trial. *Lancet* 388, 1281–1290.
- Papa, P.C., Seraphim, P.M., and Machado, U.F. (1997). Loss of weight restores GLUT 4 content in insulin-sensitive tissues of monosodium glutamate-treated obese mice. *Int. J. Obes. Relat. Metab. Disord.* 21, 1065–1070.
- Peyrin-Biroulet, L., Chamaillard, M., Gonzalez, F., Beclin, E., Decourcelle, C., Antunes, L., Gay, J., Neut, C., Colombel, J.F., and Desreumaux, P. (2007). Mesenteric fat in Crohn's disease: a pathogenetic hallmark or an innocent bystander? *Gut* 56, 577–583.
- Peyrin-Biroulet, L., Gonzalez, F., Dubuquoy, L., Rousseaux, C., Dubuquoy, C., Decourcelle, C., Saudemont, A., Tachon, M., Beclin, E., Odou, M.F., et al. (2012). Mesenteric fat as a source of C reactive protein and as a target for bacterial translocation in Crohn's disease. *Gut* 61, 78–85.
- Poletto, A.C., David-Silva, A., Yamamoto, A.P., Machado, U.F., and Furuya, D.T. (2015). Reduced Slc2a4/GLUT4 expression in subcutaneous adipose tissue of monosodium glutamate obese mice is recovered after atorvastatin treatment. *Diabetol. Metab. Syndr.* 7, 18.
- Pourgholamnejad, A., Aghdami, N., Baharvand, H., and Moazzeni, S.M. (2016). The effect of pro-inflammatory cytokines on immunophenotype, differentiation capacity and immunomodulatory functions of human mesenchymal stem cells. *Cytokine* 85, 51–60.
- Rutella, S., Zavala, F., Danese, S., Kared, H., and Leone, G. (2005). Granulocyte colony-stimulating factor: a novel mediator of T cell tolerance. *J. Immunol.* 175, 7085–7091.
- Serena, C., Keiran, N., Ceperuelo-Mallafre, V., Ejarque, M., Fradera, R., Roche, K., Nunez-Roa, C., Vendrell, J., and Fernandez-Veledo, S. (2016). Obesity and type 2 diabetes alters the immune properties of human adipose derived stem cells. *Stem Cells* 34, 2559–2573.
- Titos, E., Rius, B., Gonzalez-Periz, A., Lopez-Vicario, C., Moran-Salvador, E., Martinez-Clemente, M., Arroyo, V., and Claria, J. (2011). Resolvin D1 and its precursor docosahexaenoic acid promote resolution of adipose tissue inflammation by eliciting macrophage polarization toward an M2-like phenotype. *J. Immunol.* 187, 5408–5418.
- Van Assche, G., Dignass, A., Reinisch, W., van der Woude, C.J., Sturm, A., De Vos, M., Guslandi, M., Oldenburg, B., Dotan, I., Marteau, P., et al. (2010). The second European evidence-based consensus on the diagnosis and management of Crohn's disease: special situations. *J. Crohns Colitis* 4, 63–101.
- Yamamoto, K., Kiyohara, T., Murayama, Y., Kihara, S., Okamoto, Y., Funahashi, T., Ito, T., Nezu, R., Tsutsui, S., Miyagawa, J.I., et al. (2005). Production of adiponectin, an anti-inflammatory protein, in mesenteric adipose tissue in Crohn's disease. *Gut* 54, 789–796.
- Zubkova, E.S., Beloglazova, I.B., Makarevich, P.I., Boldyreva, M.A., Sukhareva, O.Y., Shestakova, M.V., Dergilev, K.V., Parfyonova, Y.V., and Menshikov, M.Y. (2016). Regulation of adipose tissue stem cells angiogenic potential by tumor necrosis factor- $\alpha$ . *J. Cell. Biochem.* 117, 180–196.
- Zulian, A., Canello, R., Micheletto, G., Gentilini, D., Gilardini, L., Danelli, P., and Invitti, C. (2012). Visceral adipocytes: old actors in obesity and new protagonists in Crohn's disease? *Gut* 61, 86–94.
- Zulian, A., Canello, R., Ruocco, C., Gentilini, D., Di Blasio, A.M., Danelli, P., Micheletto, G., Cesana, E., and Invitti, C. (2013). Differences in visceral fat and fat bacterial colonization between ulcerative colitis and Crohn's disease. An in vivo and in vitro study. *PLoS One* 8, e78495.

**Stem Cell Reports, Volume 9**






**Supplemental Information**

**Crohn's Disease Disturbs the Immune Properties of Human Adipose-Derived Stem Cells Related to Inflammasome Activation**



**Carolina Serena, Noelia Keiran, Ana Madeira, Elsa Maymó-Masip, Miriam Ejarque, Margarida Terrón-Puig, Eloy Espin, Marc Martí, Natalia Borrueal, Francisco Guarner, Margarida Menacho, Antonio Zorzano, Monica Millan, Sonia Fernández-Veledo, and Joan Vendrell**

**A.****B.**

**Figure S1.** ASCs isolated from VAT of CD patients showed a significant increase in the gene expression of invasive and phagocytic markers. *Related to Figure 3.* **(A)** *MMP2* and *MMP9* gene expression was analyzed by qPCR in ASCs from healthy subjects, active and inactive CD patients. **(B)** Gene expression of different phagocytic markers, *LAMP1*, *RAB5A*, and *RAB7A*, was analyzed by qPCR. N=4-10 per group as described in methods. \*P<0.05 vs healthy individuals.

**A.****B.****C.****D.****E.**

**Figure S2.** CD decreases adipogenic differentiation capacity of subcutaneous-ASCs and increases their proliferation. *Related to Figure 4.* (A) AT cell number ratio and (B) BrdU assay and (C) MTT assay were performed as explained in methods to study the cell proliferation of subcutaneous ASCs. (D) Representative image of intracellular lipid enrichment in AD from healthy, active and inactive CD individuals (magnification,  $\times 200$ ; scale bar=200 $\mu\text{m}$ ). (E) Quantification of Oil Red O staining of four independent experiments with AD from healthy, active and inactive CD individuals. N=5-10 per group as described in methods. \*P<0.05 vs healthy individuals.

**A.****B.**

**Figure S3.** Evidence of plasticity of macrophages in CD clinical remission. *Related to Figure 4.* (A) Human adipose tissue macrophages and (B) monocyte-derived peripheral blood mononuclear cells were isolated from healthy, active and inactive CD subjects and gene expression of inflammatory markers (*TNFA*, *IL1B* and *IL6*) were evaluated. n=4 per group. \*P<0.01 vs healthy status. # P< 0.005 as indicated in the figure.

## SUPPLEMENTAL EXPERIMENTAL PROCEDURES

### ***Reagents***

Dulbecco's modified Eagle's medium (DMEM) high glucose/Ham's F12 1:1, phosphate buffered saline (PBS), trypsin-EDTA and fetal bovine serum (FBS) were purchased from Thermo Fisher Scientific (Waltham, MA). Collagenase type 1, bovine serum albumin (BSA), dexamethasone, 3-isobutyl-1-methylxanthine (IBMX), biotin, human insulin solution, pantothenate acid, Oil Red O (ORO), toluidine blue and Try-Val-Ala-Asp trifluoroacetic acid (YVAD-CHO) were purchased from Sigma (St. Louis, MO). Recombinant human IL-1RA and TGF $\beta$ 1 were purchased from PreproTech (Rocky Hill, NJ). Monoclonal antibodies for flow cytometry were purchased from BD Pharmingen (San Jose, CA).

### ***Analytical determinations***

Fasting plasma glucose, total cholesterol, HDL-cholesterol, LDL-cholesterol and TG were determined by standard enzymatic methods (ADVIA 2400 Chemistry autoanalyzer. Siemens Healthcare, Erlangen, Germany). Insulin was determined by immune assay using an AVDIA Centaur XP autoanalyzer (Siemens Healthcare, Erlangen, Germany). The homeostatic model assessment (HOMA)-IR index was used to evaluate insulin resistance and was calculated as the product of fasting plasma insulin ( $\mu$ IU/mL) and fasting plasma glucose (mg/L) divided by 405.

### ***THP-1, JURKAT and MEC-1 cell culture***

The human monocyte cell line THP-1 and the human T lymphocyte cell line JURKAT were obtained from ATCC (Rockville, MD). The chronic lymphocytic leukemia cell line MEC-1 was obtained from Deutsche Sammlung von Mikroorganismen und Zellkulturen GmbH (*DSMZ*). All cells were cultured as described<sup>1-3</sup>. Briefly, cells were cultured in RPMI-1640 medium supplemented with 10% FBS and 1% antibiotic/antimycotic solution in a humidified cell culture incubator at 37°C with 5% CO<sub>2</sub>. Medium (50%) was replenished every 2–3 days.

### ***Adipogenic differentiation***

To derive mature adipocytes (mAd-ASCs), ASCs from healthy, inactive and active CD subjects were induced to differentiate according to a published protocol<sup>4</sup>. Briefly, confluent ASCs were cultured in adipogenic induction medium containing DMEM/F12 supplemented with 10% FBS, 1% penicillin/streptomycin, 1 mM dexamethasone, 500 mM IBMX, 33 mM biotin, 5 mM rosiglitazone, 100 nM insulin and 17 mM pantothenate, for three days. Cultures were replenished every 3 days with maintenance medium (supplemented medium without IBMX and rosiglitazone) for a period of two weeks, after which differentiation potential was assessed. To do this, cells were washed with PBS, fixed with 2% PFA for 30 min, and washed again with deionized water (dH<sub>2</sub>O). Adipogenic differentiation was assessed with ORO staining (0.3% ORO in isopropanol) for 1 h at room temperature, after which cells were washed with dH<sub>2</sub>O and visualized with a microscope<sup>4</sup>.

### ***Human monocytes isolation***

Human peripheral blood mononuclear cells (PBMCs) were isolated with Ficoll-Hypaque gradients (Amersham Bioscience, Barcelona, Spain). Monocytes were purified from PBMCs by magnetic cell sorting using CD14-microbeads (Milteny Biotech, S.L. Madrid, Spain) as previously described<sup>5</sup>.

### ***Human lymphocytes T naïve isolation***

Human peripheral blood mononuclear cells (PBMCs) were isolated with Ficoll-Hypaque gradients (Amersham Bioscience, Barcelona, Spain). Lymphocytes T naïve were purified from PBMCs by magnetic sorting using the Naive CD4+ T Cell Isolation Kit II (Milteny Biotech, S.L. Madrid, Spain) as previously described<sup>5</sup>.

### ***Gene expression analysis***

Total RNA was isolated from hASCs, human adipose tissue macrophages (ATM) and human monocytes using the RNeasy Lipid Tissue Mini Kit (Qiagen Science, Hilden, Germany). RNA quantity was measured at 260 nm and purity was assessed by the OD260/OD280 ratio. One microgram of RNA was transcribed to cDNA with random primers using the Reverse Transcription System (Applied Biosystems, Foster City, CA). Quantitative gene expression was evaluated by Real-time PCR (qPCR) on a 7900HT Fast Real-Time PCR System using the TaqManR Gene Expression Assay (Applied Biosystems) (genes shown in Table S2).

### ***IL-1 $\beta$ and TGF- $\beta$ 1 secretion***

The protein concentrations of IL-1 $\beta$  and TGF- $\beta$ 1 in hASC culture supernatants were determined using a double-antibody sandwich ELISA for human or mouse proteins (R&D Systems, MN).

***Succinate and Lactate release***

Extracellular succinate and lactate were measured in CM from ASCs after 24 h culture. Supernatant from at least three independent experiments was assayed using the succinate assay kit or lactate assay Kit (BioVision, Mountain View, CA).

**SUPPLEMENTAL REFERENCES**

1. Serena C, Calvo E, Clares MP, et al. Significant in vivo anti-inflammatory activity of Pytren4Q-Mn a superoxide dismutase 2 (SOD2) mimetic scorpion-like Mn (II) complex. PLoS One 2015;10:e0119102.
2. Gardiner E, Carroll A, Tooney PA, et al. Antipsychotic drug-associated gene-miRNA interaction in T-lymphocytes. Int J Neuropsychopharmacol 2014;17:929-43.
3. Belov L, Huang P, Chrisp JS, et al. Screening microarrays of novel monoclonal antibodies for binding to T-, B- and myeloid leukaemia cells. J Immunol Methods 2005;305:10-9.
4. Pachon-Pena G, Yu G, Tucker A, et al. Stromal stem cells from adipose tissue and bone marrow of age-matched female donors display distinct immunophenotypic profiles. J Cell Physiol 2011;226:843-51.
5. Maymo-Masip E, Fernandez-Veledo S, Garcia Espana A, et al. The rise of soluble TWEAK levels in severely obese subjects after bariatric surgery may affect adipocyte-cytokine production induced by TNF $\alpha$ . J Clin Endocrinol Metab 2013;98:E1323-33.

**Table S1. Immunophenotypic characterization of ASCs derived from healthy subjects, active CD and inactive CD patients.** *Related to Table 1.* The values reflect the mean  $\pm$ SD percentage surface positive staining of ASCs for a part of surface antigens including hematopoietic and stromal markers.

Antibody	Healthy-ASCs	Active CD-ASCs	Inactive CD-ASCs
CD34	12 $\pm$ 2	0,1 $\pm$ 0,05	0,2 $\pm$ 0,1
CD45	2 $\pm$ 1	0,1 $\pm$ 0,05	0,1 $\pm$ 0,1
CD73	94 $\pm$ 6	98,3 $\pm$ 0,5	96 $\pm$ 0,5
CD90	94 $\pm$ 8	96,3 $\pm$ 0,9	95,9 $\pm$ 1,1
CD105	99 $\pm$ 2	99 $\pm$ 1	98 $\pm$ 0,5

**Table S2. Human gene expression analysis.** *Related to Figures 1-6.* Results were calculated using the comparative Ct method and expressed relative to the expression of the housekeeping genes *cyclophilin 1A (PPIA)* (Hs04194521\_s1) and *18S* (Hs03928985\_g1).

Detector	Gene name
<b>Inflammation markers</b>	
<i>IL1B</i> -Hs00174097_m1	<i>Interleukin-1 beta</i>
<i>IL6</i> -Hs00985639_m1	<i>Interleukin-6</i>
<i>TNFA</i> -Hs01113624_g1	<i>Tumor necrosis factor alpha</i>
<i>CCL2/MCP1</i> -Hs00234140_m1	<i>Monocyte chemotactic protein 1</i>
<b>Anti-inflammatory markers</b>	
<i>CD163</i> -Hs00174705_m1	<i>CD163 molecule</i>
<i>MRC1</i> -Hs00267207_m1	<i>Mannose receptor, C type 1</i>
<i>ADIPOQ</i> -Hs00605917_m1	<i>Adiponectin</i>
<b>Metabolic markers</b>	
<i>SLC2A1/GLUT1</i> -Hs00892681_m1	<i>Glucose transporter type 1</i>
<i>SLC2A3/GLUT3</i> -Hs00892681_m1	<i>Glucose transporter type 3</i>
<i>SLC2A4/GLUT4</i> -Hs00168966_m1	<i>Glucose transporter type 4</i>
<i>HK2</i> -Hs00606086_m1	<i>Hexokinase 2</i>
<i>PFKM</i> -Hs00175997_m1	<i>Phosphofructokinase M</i>
<i>PDK4</i> -Hs01037712_m1	<i>Pyruvate dehydrogenase kinase, isozyme 4</i>
<i>SDHB</i> -Hs01042482_m1	<i>Succinate dehydrogenase b</i>
<i>OGDH</i> -Hs01081865_m1	<i>Alpha-ketoglutarate dehydrogenase</i>
<i>LDHB</i> -Hs00929956_m1	<i>Lactate dehydrogenase b</i>
<i>CPT1B</i> -Hs00189258_m1	<i>Carnitine palmitoyltransferase 1B</i>
<i>SLC25A2</i> -Hs00386383_m1	<i>Solute carrier family 25 member 2</i>
<i>ACAA1</i> -Hs01576064_g1	<i>Acetyl-CoA acyltransferase 1</i>
<b>Invasion markers</b>	
<i>MMP2</i> -Hs01548727_m1	<i>Metalloproteinase-2</i>
<i>MMP9</i> -Hs00234579_m1	<i>Metalloproteinase-9</i>
<b>Adipogenic markers</b>	
<i>Leptin</i> -Hs00174497_m1	<i>Leptin</i>
<i>PPARG</i> -Hs01115513_m1	<i>Peroxisome proliferator-activated receptor gamma</i>
<i>FABP4</i> -Hs01086177_m1	<i>Fatty acid binding protein 4</i>
<i>LPL</i> -Hs00173425_m1	<i>Lipoprotein lipase</i>
<b>Inflammasome compounds</b>	
<i>CASP1</i> -Hs00354836_m1	<i>Caspase 1</i>
<i>NLRP1</i> -Hs00248187_m1	<i>NACHT, LRR and PYD domains-containing protein 1</i>
<i>NLRP3</i> -Hs00918082_m1	<i>NACHT, LRR and PYD domains-containing protein 3</i>
<b>Phagocytic markers</b>	
<i>LAMP1</i> -Hs00174766_m1	<i>Lysosomal-associated membrane protein 1</i>
<i>RAB5A</i> -Hs00991290_m1	<i>Member RAS oncogene family</i>
<i>RAB7A</i> -Hs01115139_m1	<i>Member RAS oncogene family</i>
<b>Th1 markers</b>	
<i>IL2</i> -Hs00174114_m1	<i>Interleukin-2</i>
<i>IL12B</i> -Hs 01011518_m1	<i>Interleukin-12 b</i>
<i>TBX21</i> -Hs00894392_m1	<i>T-box transcription factor 21</i>
<i>IFNG</i> -Hs00989291_m1	<i>Interferon gamma</i>
<b>Th2 markers</b>	
<i>GATA3</i> -Hs00231122_m1	<i>Trans-acting T-cell-specific transcription factor-3</i>
<i>GCSF/CSF3</i> -Hs00738432_m1	<i>Granulocyte-colony stimulating factor</i>
<i>TGFB1</i> -Hs 00998133_m1	<i>Transforming growth factor beta 1</i>
<i>STAT6</i> -Hs00598625_m1	<i>Signal transducer and activator of transcription 6</i>